Cargando…
Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
There is a growing interest in using monoclonal antibodies (mAbs) in the early stages of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent disease progression. Little is known about the efficacy of mAbs against the delta variant of concern and its clinical presentatio...
Autores principales: | Cicchitto, Gaetano, Cardillo, Lorena, de Martinis, Claudio, Sabatini, Paola, Marchitiello, Rosita, Abate, Giovanna, Rovetti, Adele, Cavallera, Antonietta, Apuzzo, Camillo, Ferrigno, Francesco, Fusco, Giovanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950724/ https://www.ncbi.nlm.nih.gov/pubmed/35337057 http://dx.doi.org/10.3390/v14030650 |
Ejemplares similares
-
Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022) -
Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
por: Folkman, Rebecca, et al.
Publicado: (2022) -
Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021) -
Casirivimab and imdevimab for COVID-19
Publicado: (2022) -
Casirivimab/imdevimab: Lack of efficacy: case report
Publicado: (2022)